Internal Reference Number: FOI_7759
Date Request Received: 14/02/2024 00:00:00
Date Request Replied To: 05/03/2024 00:00:00
This response was sent via: By Email
Request Summary: Lung cancer
Request Category: Researcher
| Question Number 1: How many Non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) • Amivantamab • Atezolizumab Monotherapy • Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel • Dabrafenib + Trametinib • Docetaxel monotherapy or in combination with Carboplatin/Cisplatin • Durvalumab • Gemcitabine • Nitedanib + Docetaxel • Nivolumab • Osimertinib • Other EGFR Inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) • Paclitaxel • Pembrolizumab Monotherapy • Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) • Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin) • Pemetrexed + Platinum (Carboplatin/Cisplatin) • RET Inhibitors (Pralsetinib, Selpercatinib) • Sotorasib • Tepotinib • Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin • Other active systemic anti-cancer therapy • Palliative care only | |
| Answer To Question 1: • ALK Inhibitors (Alectinib, Brigatinib, Ceritinib, Crizotinib, Lorlatinib) 8 • Amivantamab- 0 • Atezolizumab monotherapy 6 • Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel 0 • Dabrafenib + Trametinib- <5 • Docetaxel monotherapy or in combination with Carboplatin/Cisplatin 0 • Durvalumab – <5 • Gemcitabine - 0 • Nitedanib + Docetaxe <5 • Nivolumab 0 • Osimertinib 16 • Other EGFR inhibitors (Afatinib, Erlotinib, Gefitinib, Dacomitinib, Mobocertinib) <5 • Paclitaxel - 0 • Pembrolizumab monotherapy - 7 • Pembrolizumab + Paclitaxel + Platinum (Carboplatin/Cisplatin) 0 • Pembrolizumab + Pemetrexed + Platinum (Carboplatin/Cisplatin)- 16 • Pemetrexed + Platinum (Carboplatin/Cisplatin) <5 • RET inhibitors (Pralsetinib, Selpercatinib) 0 • Sotorasib <5 • Tepotinib <5 • Vinorelbine monotherapy or in combination with Carboplatin/Cisplatin– <5 • Other active systemic anti-cancer therapy <1 • Palliative care- unable to answer | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
